scholarly journals Resistances to EGFR tyrosine kinase inhibitors in lung cancer—how to routinely track them in a molecular pathology laboratory?

2019 ◽  
Vol 11 (S1) ◽  
pp. S65-S70 ◽  
Author(s):  
Véronique Hofman ◽  
Paul Hofman
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Molecular Pathology ◽  
Kinase Inhibitors ◽  
Pathology Laboratory ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors

scholarly journals Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1590
Author(s):  
Kenichi Suda ◽  
Tetsuya Mitsudomi
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Molecular Mechanisms ◽  
Kinase Inhibitors ◽  
Drug Tolerance ◽  
Lung Cancers ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutated

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) serve as the standard of care for the first-line treatment of patients with lung cancers with EGFR-activating mutations. However, the acquisition of resistance to EGFR TKIs is almost inevitable, with extremely rare exceptions, and drug-tolerant cells (DTCs) that demonstrate reversible drug insensitivity and that survive the early phase of TKI exposure are hypothesized to be an important source of cancer cells that eventually acquire irreversible resistance. Numerous studies on the molecular mechanisms of drug tolerance of EGFR-mutated lung cancers employ lung cancer cell lines as models. Here, we reviewed these studies to generally describe the features, potential origins, and candidate molecular mechanisms of DTCs. The rapid development of an optimal treatment for EGFR-mutated lung cancer will require a better understanding of the underlying molecular mechanisms of the drug insensitivity of DTCs.

scholarly journals V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors

2014 ◽  
Vol 9 (9) ◽  
pp. 1377-1384 ◽  
Author(s):  
Satsuki Matsushima ◽  
Kouki Ohtsuka ◽  
Hiroaki Ohnishi ◽  
Masachika Fujiwara ◽  
Hiroyuki Nakamura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Egfr Mutation ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors

Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer

2021 ◽  
pp. canres.2811.2020
Author(s):  
Yukie Kashima ◽  
Daisuke Shibahara ◽  
Ayako Suzuki ◽  
Kyoko Muto ◽  
Ikei S. Kobayashi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Single Cell ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Mechanisms Of Resistance ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors

EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19117-19117
Author(s):  
D. M. Kowalski ◽  
M. Krzakowski ◽  
P. Jaskiewicz ◽  
A. Janowicz-Zebrowska ◽  
M. Glogowski
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors

scholarly journals Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

2011 ◽  
Vol 17 (19) ◽  
pp. 6322-6328 ◽  
Author(s):  
Geoffrey R. Oxnard ◽  
Yelena Y. Janjigian ◽  
Maria E. Arcila ◽  
Camelia S. Sima ◽  
Samantha L. Kass ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutant
Sign in / Sign up

Export Citation Format

Share Document